Join our daily newsletter At The Bell to receive exclusive market insights
- CardieX (CDX) subsidiary ATCOR has been granted a new patent for its blood pressure measurement technologies which brings its total patents to 14
- The patent was awarded by the U.S Patent & Trademark Office for the company’s non-invasive blood pressure measurement
- More specifically, the patent relates to CardieX’s SphygmoCor technology, which it describes as the “global gold standard” for assessing the shape of the pulse and the stiffness of the arteries at a person’s heart
- The patent is set to remain in force until 2038
- CardieX shares are up 1.56 per cent following the news, trading at 6.5 cents
CardieX(CDX) subsidiary ATCOR has been granted a new patent for its blood pressure measurement technologies which brings its total patents to 14.
U.S Patent 11,006,842 titled “Non-Invasive Brachial Blood Pressure Measurement” was awarded to CardieX by the U.S Patent & Trademark Office and is set to remain in force until 2038.
According to CardieX, the patent is set to protect the company’s intellectual property in relation to the measurement of central blood pressure waveforms using a brachial blood pressure cuff via its SphygmoCor technology.
CardieX describes SphygmoCor as the “global gold standard” for assessing the shape of the pulse and the stiffness of the arteries at a person’s heart.
More broadly, the ASX-lister said it further enhances its intellectual property in this area.
In May 2020, ATCOR also lodged an additional new patent application for what is said to be a world-first wearable sensor technology method, CardieX said is incorporating into upcoming product releases.
CardieX’s shares are up 1.56 per cent following the news, trading at 6.5 cents at 12:56 pm AEST.
